The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ctDNA features of acquired resistance to immunotherapy in advanced NSCLC.
 
Sofiane Taleb
No Relationships to Disclose
 
Letuan Phan
No Relationships to Disclose
 
Sophie Cousin
Honoraria - AstraZeneca; MSD Oncology; Sanofi; Takeda
Consulting or Advisory Role - Janssen Oncology
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Pfizer; Takeda
 
Etienne Rouleau
Employment - Thermofisher Scientific Biomarkers (I)
Honoraria - AstraZeneca (Inst); BMS (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); Roche (Inst)
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS
 
Laura Leroy
No Relationships to Disclose
 
Isabelle Soubeyran
Research Funding - AstraZeneca (Inst)
 
David Planchard
Honoraria - Medscape; PeerVoice; Prime Oncology
Consulting or Advisory Role - Abbvie; Anheart Therapeutics; ArriVent Biopharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; Gilead Sciences; Janssen; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Samsung; Seagen
Research Funding - Abbvie (Inst); ArriVent Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Melissa Alame
Travel, Accommodations, Expenses - AstraZeneca
 
Ludovic Lacroix
No Relationships to Disclose
 
Laura Blouin
No Relationships to Disclose
 
Jean-Charles Soria
No Relationships to Disclose
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; BMS; Celgene; Debiopharm Group; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Genentech/Roche; INNATE PHARMA; IPSEN; Janssen; Lilly; MSD; Novartis; ORION; Pfizer; PharmaMar; Sanofi; Taiho Pharmaceutical
 
Fabrice Barlesi
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai Europe (Inst); Lilly (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Amandine Crombe
No Relationships to Disclose
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS